(0.31%) 5 034.03 points
(0.35%) 38 035 points
(0.70%) 15 715 points
(-0.05%) $78.96
(4.45%) $2.02
(-0.02%) $2 310.50
(0.26%) $26.82
(0.86%) $963.10
(0.06%) $0.934
(-0.06%) $11.02
(0.09%) $0.799
(-1.37%) $91.98
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 8.49%
@ $58.15
发出时间: 15 Feb 2024 @ 04:11
回报率: -1.31%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 4.68 %
Live Chart Being Loaded With Signals
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need...
Stats | |
---|---|
今日成交量 | 92 900.00 |
平均成交量 | 361 314 |
市值 | 2.07B |
EPS | $-1.340 ( 2024-03-01 ) |
下一个收益日期 | ( $-1.350 ) 2024-05-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.04 |
ATR14 | $0.116 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Regnante Keith | Buy | 40 000 | Employee Stock Option (right to buy) |
2024-02-13 | Rovaldi Christopher | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Cooper Simon Peter | Buy | 40 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
67.74 |
Last 96 transactions |
Buy: 1 546 013 | Sell: 365 314 |
音量 相关性
Keros Therapeutics Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Keros Therapeutics Inc 相关性 - 货币/商品
Keros Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $151 000 |
毛利润: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2023 |
营收: | $151 000 |
毛利润: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.62M (0.00 %) |
EPS: | $-4.15 |
FY | 2021 |
营收: | $20.10M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.52 |
Financial Reports:
No articles found.
Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。